The mouse Sno gene, a Ski proto-oncogene homolog, expresses two isoforms, SnoN and SnoN2 (also called sno-dE3), which differ from each other in a location downstream from the site of alternative splicing previously described in the human SNO gene. SnoN2 is missing a 138 nt coding segment present in mouse SnoN and human SNON. We have cloned and sequenced the human ortholog of mouse SnoN2, the existence of which was predicted from conservation of the alternative splice donor site that produces the SnoN2 isoform. Mouse SnoN2 and SnoN are expressed throughout embryonic development, in neonatal muscle and in many adult tissues. SnoN2 is the major species in most tissues, but SnoN and SnoN2 are expressed at approximately equal levels in brain. In human tissues, SNON2 is the less abundantly expressed isoform. Expression of mouse SnoN and SnoN2 mRNAs is induced with immediate early kinetics upon serum stimulation of quiescent fibroblasts, even in the presence of the protein synthesis inhibitor cycloheximide, while Ski is not. Interestingly, although both isoforms of Sno are induced, SnoN2 induction is much higher than SnoN. These data are consistent with a role for Sno in the response to proliferation stimuli.
INTRODUCTION
Ski and Sno each have the paradoxical property that they can promote both oncogenic transformation, in which cell proliferation increases, and terminal skeletal muscle differentiation, in which cells withdraw from the cell cycle (1, 2) . Thus, they may affect the responses of myoblasts to extracellular signals by proliferating or undergoing terminal differentiation. The v-Ski oncogene was isolated as the transforming component of Sloan-Kettering virus (SKV); when overexpressed, Ski can transform chicken embryo fibroblasts (3) (4) (5) . Paradoxically, overexpression of either v-Ski or chicken c-Ski can also convert non-myogenic avian cells to the myogenic lineage (1) . A mutant Ski, tdM5i, fails to convert the cells to muscle, but retains its ability to transactivate the endogenous MyoD and myogenin genes (6) . Since activation of MyoD and myogenin is insufficient to convert these cells to muscle in the presence of mutant SKI protein, SKI may play a role in myogenic conversion and may function in myogenesis in conjunction with MyoD. Transgenic mice overexpressing a truncated cloned chicken c-Ski cDNA in their skeletal muscles exhibit a marked enlargement of these muscles, specifically type IIb fast myofibers, and diminished body fat (7, 8) . The enlarged skeletal muscle phenotype suggests that SKI affects skeletal muscle development and/or maturation. Ski expression is low in developing muscle precursors in embryos and is thus probably not involved in determination (1, 9) , but is high in regions that are undergoing active proliferation and differentiation in the muscle (1, 9) , hematopoietic (10) (11) (12) and neural lineages (13) .
The human Sno gene (for Ski-related novel) was identified by cloning in low stringency hybridization screens of human cDNA libraries with the chicken v-Ski probe (14, 15) . Sno, like Ski, can convert non-muscle quail embryo cells to skeletal muscle and has weak transforming activity (2) . SKI and SNO proteins are found in the nucleus, but are not members of any recognized transcription factor gene family. Human SNO and SKI share a 106 amino acid region in the N-terminal half of each protein that is 82% identical; the two proteins are 37% identical throughout their length, which is more similarity than members of many families. SKI protein can form a complex with SNON through a C-terminal region that includes a putative α-helical coiled coil structure (16, 17) . Three isoforms of human SNO, SNON, SNOA and SNOI, have been cloned as cDNAs (14, 15) . These isoforms differ by inclusion of mutually exclusive alternative exons A (Alu-containing), N (non-Alu-containing) or I (insertion). SNON and SNOA mRNAs are expressed in many human tissues, including skeletal muscle, but the SNOI isoform is limited to skeletal muscle and found in the skeletal muscle-containing rhabdomyosarcoma tumor (15) . Cross-hybridization to sequences related to the SnoI alternative isoform is found in non-rodent mammalian species, including dogs, cows and rabbits (15) , but is not found in chickens (2) or mice (15) . This paper extends the results of Pelzer et al., who described two alternatively spliced isoforms of Sno in mice, SnoN and sno-dE3, which we call SnoN2 (18) . We describe the expression of these isoforms in additional tissues in mice and find that SnoN2 is 80% of the expressed Sno mRNA in most tissues, but ∼50% in the brain. We have cloned and sequenced human SNON2. In humans SNON2 is a smaller fraction of the accumulated SNO mRNA population and previous workers were unable to detect it (18) . We show that Sno expression is induced with immediate early kinetics within 30 min of serum stimulation of quiescent mouse fibroblasts, even in the presence of the protein synthesis inhibitor cycloheximide, but Ski is not. Interestingly, although both isoforms of Sno are induced, SnoN2 induction appears to be much stronger than SnoN. Our data are consistent with the possibility that Sno may have a regulatory role in cells such as myoblasts when they divide or differentiate in response to extracellular signals.
MATERIALS AND METHODS

Cell culture
C2 (sometimes called C2C12; 19, 20) and 10T1/2 cells were obtained from the American Type Tissue Collection and were cultured in Dulbecco's modified Eagle's medium (DMEM) (C2) or basal medium Earle's (BME) (10T1/2) medium with 10% fetal calf serum on gelatinized plates. FDC-P1 cells, growth factordependent mouse myeloid cells provided by Dr J.N.Ihle (21, 22) , were cultured in DMEM with 10% fetal calf serum and 25% WEHI-conditioned medium, which supplies IL-3 that the cells require for proliferation. 23A2 mouse myoblasts were derived from C3H 10T1/2 (clone 8) cells following 5-azacytidine treatment and subcloning of determined myoblasts (23) . 23A2 cells were cultured on gelatinized plates in BME supplemented with 15% fetal calf serum.
10T1/2 cells were made quiescent by culture of confluent dishes in medium containing 0.5% fetal calf serum for 3 days. Serum stimulation consisted of replacing the low serum medium with medium containing 20% fetal calf serum, either with or without supplementation with 10 µg/ml cycloheximide.
RNA isolation
RNA was isolated from tissue culture cells or from mouse embryos or tissues by homogenization in guanidinium thiocyanate and ultracentrifugation through CsCl (24, 25) . Poly(A) + RNA was selected by chromatography on oligo(dT)-cellulose using Pharmacia Type 7 (dT)-cellulose.
Library synthesis and screening
Poly(A) + RNA isolated from subconfluent 23A2 mouse myoblasts (23) was used to make the cDNA library. Double-stranded cDNA was synthesized by the method of Gubler and Hoffman (26) , using RT-XL AMV reverse transcriptase (Life Sciences Inc., St Petersburg, FL) for first strand cDNA synthesis. The cDNA was treated with EcoRI methylase (New England Biolabs) and EcoRI linkers were used for ligation to λgt10 phage arms (Stratagene); phage were packaged using Gigapack Gold extract (Stratagene). From 3.5 µg of poly(A) + RNA, 1.0 × 10 6 recombinants were isolated; the library was amplified once prior to screening. To isolate mouse Ski homologs, 400 000 plaque forming units (p.f.u.) of recombinant phage were plated at a density of 40 000 p.f.u./150 mm plate. Duplicate plaque lifts on nitrocellulose filters (Schleicher and Schuell) were prehybridized in 6× SSC, 10× Denhardt's (0.2% each of Ficoll 400, polyvinylpyrrolidone and bovine serum albumin) for 5 h and hybridized in 1 M NaCl, 50 mM Tris, pH 7.4, 2 mM EDTA, 10× Denhardt's, 50 µg/ml sonicated denatured salmon sperm DNA, 2.5 µg/ml each poly(A), poly(U), poly(I) and poly(C) and 0.5% SDS at 60_C for 60 h (27) . The filters were hybridized with a random hexamer-primed fragment from the human SNOI cDNA that cross-hybridizes with any isoform of Sno (15) . Filters were washed at 50_C as described (27) , plus a final 0.3× SSC wash at 50_C. Several positives were rescreened and plaque purified; one was the 2018 bp SnoN2 described here.
DNA sequencing
cDNA clone fragments were subcloned in pGEM7zf(+) (Promega) and unidirectional nested deletions were made for sequencing (28) (Erase-A-Base; Promega). Double-stranded DNA primed by pUC/M13 universal or reverse sequencing primers or specific oligonucleotides was sequenced by the dideoxy chain termination method (29, 30) , sequencing both strands of the DNA.
Reverse transcription-PCR (RT-PCR)
Aliquots of 10 µg total RNA from the indicated mouse tissue, cell line or bone marrow sample were reverse transcribed using random hexamer primers and AMV reverse transcriptase (Boehringer Mannheim). A portion of the first strand cDNA was then amplified using 'hot start', Vent DNA polymerase (New England Biolabs), and the indicated specific primers at 0.4 µM each plus 10 µCi [ 32 P]dCTP at 3000 Ci/mmol. Following an initial denaturation at 95_C for 3 min, the 27 cycles consisted of 95, 62 and 72_C for 1 min each, plus a final elongation at 72_C for 7 min. The number of cycles and amount of reverse transcribed RNA that was used for PCR were chosen in pilot experiments so that the reactions were in the linear range with respect to amount of input RNA (31) . A sample size of 1.4 µg was used for Sno amplifications from tissue samples, 0.6 µg for Sno induction in 10T1/2 cells and 0.1 µg was used for GAPDH primer PCR. Aliquots of 10 µl of each 50 µl sample after PCR were subjected to 5% acrylamide gel electrophoresis (BioRad), then gels were dried, autoradiographed and analyzed using a phosphorimager (Molecular Dynamics). GAPDH primers were Clontech 5406-1 for human and 5409-1 for mouse. Additional oligonucleotide primer sequences are in Table 1 . Oligonucleotides oH075 and oH074 (Table 1) amplify human SNON as a 308 nt product and the human SNON2 variant that deletes the 138 nt as a shorter species (170 nt) (Figs 1 and 6 ). Oligonucleotides oM094 and oM065 amplify a 427 nt product (1302-1729) from mouse SnoN and a 289 nt product (1302-1591) from mouse SnoN2 (Figs 1 and 6 ).
RT-PCR cloning
Reverse transcribed 11.5 day mouse embryo total RNA, which expresses both SnoN2 and SnoN isoforms, was primed with oM051 and oM054 using Expand High Fidelity enzyme mix (Boehringer Mannheim Inc.) to obtain SnoN and additional SnoN2 clones. The PCR was programed for 3 min at 95_C, 10 cycles of 94_C for 1 min, 55_ for 1 min, 72_C for 2 min, 10 cycles of the same with 20 s annealing cycle extension, then 7 min at 72_C. PCR product was digested with BamHI and SalI, then cloned into pGEM37f(+) cut with BamHI and SalI. The same protocol was used for cloning human SNON2 and variants, with human kidney RNA and oligonucleotide primers oH070 and oH072. 
RNase protection
The riboprobe for SnoN was prepared from a subcloned 5′-end cDNA fragment terminating at the PstI site at nt 1678 ( Fig. 3A ) in the pGEM 3zf(+) vector (Promega). The plasmid was cleaved at the BstEII site at nt 1207, then used with the SP6 primer and [ 32 P]UTP (800 Ci/mmol; NEN) in vitro to transcribe a uniformly labeled single-stranded RNA probe. A cyclophilin template (Ambion) was used to make a cyclophilin probe in parallel. Both probes were gel purified on a denaturing 6% acrylamide gel prior to use. In pilot studies we determined that the abundance of cyclophilin over Sno RNA required 20-fold dilution of the cyclophilin probe to keep the band intensities within range. Thus, we mixed 10 5 c.p.m. of SnoN and 5000 c.p.m. of cyclophilin gel purified, in vitro transcribed [ 32 P]UTP-labeled riboprobes with each 50 µg total RNA sample. These were denatured at 90_C and annealed overnight at 42_C. Samples were treated with RNase A/RNase T1 as described (Ambion #1410), ethanol precipitated and electrophoresed on a denaturing 6% acrylamide gel. Gels were dried and signal intensities visualized and analyzed with a phosphorimager (Molecular Dynamics).
RESULTS
Cloning and nucleotide sequence of mouse and human
SnoN2 and SnoN
We cloned a mouse Sno homolog, SnoN2, from a myoblast cDNA library using a human SNO cDNA probe that cross-hybridizes with all isoforms of Sno (15) . This isoform has also been called sno-dE3 (18) . The mouse SNON2 predicted protein structure most closely resembles the human SNON isoform, rather than the shorter human SNOA and SNOI proteins (14, 15) . Mouse SnoN2 differs from SnoN by deletion of 138 nt (46 predicted amino acid residues, at amino acid 426; Figs 1 and 6). We used RT-PCR to clone the mouse SnoN ortholog of the human SNON isoform (Fig. 1) . Except for the 138 nt deletion, SnoN is identical to SnoN2, containing four additional small deletions that make mouse SNO proteins 10 amino acids shorter than human SNO ( Fig. 1; 18 ). Mouse SNON2 protein differs from the human and chicken SNON sequences at five locations in two clusters where amino acid residues encoded in human SNON are absent from the mouse coding sequence (Fig. 1) . Chicken SNON has all of the human amino acid residues and six additional, for a total of 690 residues (2) . There are two locations where single amino acid residues present in chicken SNO are absent from both mouse and human SNO. Mouse SNON and SNON2 retain a high degree of similarity with human SNON and chicken SNON (Fig. 1) , with no deletions in the most highly conserved sections of the proteins nor in the C-terminal region that interacts with another molecule of SNON or with SKI (amino acid residues 540-595 and 632-674 in human SNON, predicted to form an α-helical coiled coil structure; Fig. 1 ; 16,17,32).
Human Sno isoforms and expression
Alignment of the mouse, human and chicken Sno sequences at the site of the 138 nt deletion shows that mouse and human share a consensus splice donor sequence, whereas chicken does not ( Fig. 2A) , as noted previously (18) . To determine if human cells express the SNON2 mRNA species that is predicted from conservation of the consensus splice donor sequence and its use in mouse SnoN2, we performed RT-PCR using human total RNA and primers that flank the SNON2 alternative splice site. These primers do not span the SNOI/SNOA alternative splice location and thus should detect SNON (311 nt) and SNON2 (173 nt), but not SNOA or SNOI (Fig. 6 ). Humans express a SNON2 species at low levels in addition to the major SNON species (Fig. 2C) . We confirmed that these PCR bands both contain SNON sequence by PCR amplification without radionuclides and hybridization with a human SNO probe (data not shown). We cloned and sequenced three SNON2 clones from human tissue. These nucleotide sequences confirm that human SNON2 is spliced as in the mouse, remaining in-frame and predicting the translation of a similar SNON2 protein missing 46 amino acid residues (Figs 1 and 6 ). This is the first report of the human SNON2 isoform. Phosphorimager quantitation in both blot and 32 P PCR experiments showed that human SNON2 is expressed at 1-2% of the level of SNON RNA. It is possible that this is an overestimate of human SNON2, since smaller species can PCR amplify preferentially (although this did not happen with mouse SnoN2; Fig. 5A and B). This contrasts with the mouse, where SnoN2 is often the most abundant Sno isoform expressed (Figs 3B and 5).
Mouse and human Sno exon boundaries
We examined several questions about the mammalian Sno exon structure. We confirmed that mouse Sno shares the exon 1/2 junction position with chicken Sno and with Ski by nucleotide sequencing of a genomic clone that includes exon 1 (data not shown). Chicken Sno has an intron in the 5′-untranslated region chicken Sno exon boundaries are below the lines; they differ at two points, the absence of the exon 2/3 subdivision and the shift in the exon 4/5 junction by one amino acid residue (33) . The alternative splice donor site in mouse and human SNO is indicated with an arrow above the sequence stack in mouse exon 3 and the missing amino acids by dashes. The absence of the corresponding alternative splice donor in chicken Sno is indicated with a null symbol (O) below the stack. The putative α-helical coiled coil domains near the C-terminus are double underlined (16, 17, 32) . The alignment was done using the MSA (42) and SSEARCH programs (43) . The mouse SnoN2 GenBank/EMBL accession no. is U14655; SnoN is U36203; human SNON2 is U70730. (33) . We used PCR to compare reverse transcribed RNA with genomic DNA templates and found that mouse Sno does not interrupt the 500 nt 5′-untranslated region with an intron; PCR across this region produces the same size product whether the template is reverse transcribed RNA or genomic DNA (data not shown). Thus, the largest coding exon, which is exon 2 in chicken Sno, is exon 1 in mammalian Sno (Figs 1 and 6) . A small exon 2 in mouse Sno has been proposed and its junction locations were confirmed by sequencing the genomic DNA around exon 3 (18) . This exon 2 is not a separate exon in the chicken Sno gene ( Fig. 1; 18,33) . [This should not be confused with the unrelated 'exon 2' that is present in v-ski and alternatively spliced in chicken c-Ski (34, 35) , which is not conserved in Sno or in mammalian Ski.] It has been shown that the alternatively spliced exon 3 is continuous in genomic mouse DNA and that alternative splicing of the SnoN2 region is not due to exclusion of an exon that consists only of the region that is deleted in SnoN2 (18) . We determined the nucleotide sequences of RT-PCR cloned human variants that lack exon 3 and those that lack both exons 2 and 3 and found that the 2/3 and 3/4 exon boundaries are conserved between the mouse and human Sno genes. The human SNO variant clones that correspond to the omission of exon 3 (SNOD3 for deletion of exon 3) and those missing both exons 2 and 3 (SNOD23 for deletion of exons 2 and 3) would, if expressed, predict the expression of truncated proteins with short, unique primary sequences at their C-termini. However, expression of these forms is very low and not detected in RT-PCR experiments (data not shown), raising questions about whether they are expressed to any significant extent. Nevertheless, the nucleotide sequences of these variants suggest that the 2/3 and 3/4 exon boundaries are conserved between the mouse and human Sno genes (Fig. 1) .
Analysis of SnoN and SnoN2 expression
We examined mouse SnoN and SnoN2 expression in a variety of tissues using RNase protection with a radiolabeled SnoN riboprobe (Fig. 3) . Full-length protection of the probe by SnoN gives a 471 nt band, which is only slightly shorter than the 493 nt of the complete probe vector. Digestion of the 493 nt non-annealed probe by RNase is complete, as shown by the absence of signal in the 'yeast RNA + RNase' lane (Fig. 3B) ; the SnoN band seen is the protected 471 nt band. Annealing of SnoN2 mRNA to the probe protects a 199 nt band (3′ of the SnoN2 deletion) and 134 nt band (5′ of the SnoN2 deletion) from RNase cleavage (Fig. 3A  and B) . Both mouse SnoN2 and SnoN were detected in all of the mouse tissues examined; expression of both was low in liver (Fig. 3B) . SnoN2 is much more abundant than SnoN in leg muscle, liver, small intestine, spleen and thymus, averaging 80% of the Sno signal. In brain, SnoN2 is 50% of the Sno RNA. Similar results have been obtained on another set of tissues, including uterus, fat, lung, large intestine, kidney, heart, cerebrum and cerebellum (18) . Thus, SnoN and SnoN2 are expressed in most tissues, with some differences in the ratio of the two forms and SnoN2 usually the more abundant species.
Cultured cells, including the mouse myeloid growth factordependent cell line FDC-P1 and 10T1/2 fibroblasts, express SnoN2 and some SnoN (Figs 3 and 4) . SnoN2 and SnoN mRNA isoforms are expressed throughout embryonic development, as well as in proliferating embryonic stem cells and differentiating embryoid bodies (Pearson-White, unpublished data). SnoN2 and SnoN are expressed in neural cells and during skeletal myogenesis in embryos, especially sites of active cellular proliferation (18) . We consistently observe a reduced level of expression of mouse SnoN isoforms in adult skeletal muscle, which seems potentially contrary to the expectation that Sno may function in skeletal myogenesis. Although in this example the adult skeletal muscle lane in Figure 3B has less RNA, we and others have observed reduced Sno expression in adult muscle using Northern blot analysis, RNase protection and RT-PCR (data not shown and 18). Sno expression is higher in neonatal skeletal muscle from birth through 2 weeks (1 week shown in Fig. 3B ). This is consistent with a potential role for Sno in skeletal myogenesis in proliferating myoblasts and satellite cells. Sno expression is not down-regulated in the brain, where it remains constant from early postnatal development through adulthood (adult brain shown in Fig. 3B and time course not shown). 
A B
SnoN responds to growth factor addition with immediate early kinetics
Many nuclear proto-oncogenes and/or transcription factors are induced by serum stimulation of quiescent cells, responding within the first 2 h after stimulation (36) (37) (38) . We have previously shown that Sno and Ski are cell cycle regulated in synchronized cycling myeloid cells, peaking in the early to mid G 1 phase of the cell cycle (12) . To examine whether Sno and Ski exhibit cell cycle regulation in another cell type and as part of the characterization of Sno, we examined Sno and Ski expression in response to serum stimulation of serum-deprived fibroblasts. Quiescent 10T1/2 cells were stimulated with serum and RNA was isolated at various times thereafter. These RNA samples were then electrophoresed, blotted and hybridized with the SnoN probe.
SnoN/N2 expression increases within 4 h of serum stimulation (Fig. 4, left panel) . SnoN and SnoN2 are not resolved on this blot, as they differ from each other by 138 nt in a 7.6 kb mRNA. Two bands, at 7.6 and 3.6 kb, hybridize with the SnoN probe in the Northern blot (Fig. 4) ; the shorter band results from cleavage of the mRNA in the 3′-untranslated region (13) . The protein synthesis inhibitor cycloheximide did not inhibit Sno mRNA induction after serum stimulation. Thus, according to the definition of immediate early genes as those that are induced without requiring protein synthesis and delayed early genes as those that require protein synthesis for induction, Sno is an immediate early gene. Sno levels are higher and more persistent when serum stimulation is in the presence of cycloheximide, thus exhibiting the superinduction that is typical of immediate early genes, especially those that undergo rapid mRNA turnover. Reprobing the blots with pAL15, which encodes a mitochondrial ribosomal protein subunit whose expression does not vary with the cell cycle (39) , shows that the lanes are approximately equally loaded with RNA, except for the 2 h minus-cycloheximide time point (Fig. 4) . These results show that Sno responds to growth factor stimulation of cells with kinetics typical of immediate early response genes. We reprobed the blot to examine a prototypical immediate early response gene, c-jun (38) ; it showed the expected immediate early kinetics (Fig. 4) .
We calculated the fold induction by dividing the maximal phosphorimager Northern blot signals (in arbitrary units) by the units measured at the zero time point for each probe, after background subtraction. The fold increases are only approximate; small changes in the measurement for the zero time point cause large changes in the calculated fold increase. We calculated an ∼7-fold increase in Sno mRNA signal between the zero and 30 min time points, but this is not apparent from the autoradiogram shown (Fig. 4, right panel) . We calculated a 40-fold induction of Sno in the absence of cycloheximide and ∼300-fold in its presence between the zero time point (65 U) and the 4 h peak (20 683 U). For comparison, we calculated 7-fold induction of c-jun in the absence of cycloheximide and 14-fold in its presence.
To examine the induction of SnoN and SnoN2 separately, we performed RT-PCR (Fig. 5A ) and RNase protection (Fig. 5B) on the RNA samples used for the Northern blot in Figure 4 . SnoN2 is the more abundant mRNA after serum stimulation, especially in the presence of cycloheximide. Both isoforms are ∼10-fold induced in the absence of cycloheximide (Fig. 5A) . However, SnoN is induced ∼10-fold, while SnoN2 is induced ∼80-fold in the (Fig. 5A) , calculated by dividing the units measured at the 4 h peak by those obtained at the zero time point, both after background subtraction. We did not have enough RNA remaining to repeat the zero time point by RNase protection, but noted induction that was very similar to that obtained by RT-PCR. By RNase protection we calculated ∼10-fold induction of SnoN and ∼150-fold induction of SnoN2, by dividing the maximal signal in arbitrary units by that obtained at 30 min. (This is an underestimate of the induction, since there is some induction between 0 and 30 min.) Thus, the results show that it is the SnoN2 isoform that is responsible for most of the induction after serum stimulation in the presence of cycloheximide and for the superinduction.
Ski is expressed at constant levels in quiescent cells and throughout the time course after serum stimulation (Fig. 4) and remains constitutive in the presence of cycloheximide. Phosphorimager quantitation of the Northern blot confirmed that Ski mRNA is expressed at a constant low level throughout the time course, although a slight decrease is noted at 10 and 24 h (Fig. 4) . (16, 32) . These two predicted α-helical coiled coil domains share 41 and 51% identity between human SKI and SNO (16) and are within the region required for interaction between SKI and SNO proteins (16, 17) . Pairs of PCR primers used in Figures 2C (human) and 5A (mouse) are represented. Exon boundaries are shown above the mouse SNON bar.
The 6.6 and 5.3 kb Ski species appear indistinct and are not resolved in the figure; they are only 2 mm apart on this short gel and the low hybridization intensity contributes to the lack of resolution (Fig. 4) . Since reprobing the blot with a higher specific activity Ski probe did not improve this, we performed RT-PCR on the RNAs using Ski primers and confirmed that Ski mRNA is expressed constitutively and not induced by serum stimulation (data not shown).
DISCUSSION
The mouse Sno gene encodes two variants of SnoN, SnoN and SnoN2 (which has also been called sno-dE3; 18). Mouse orthologs of human SNOA or SNOI have not been detected. Human and mouse Sno genes are single copy (15) . Mouse Sno variants SnoN2 and SnoN differ from each other only by inclusion (SnoN) or exclusion (SnoN2) of a 138 nt segment encoding 46 amino acids in-frame. Pelzer et al. have proposed that these 46 amino acids encode several potential kinase recognition domains (18) . SnoN2 has also been called sno-dE3 for deleted in exon 3 (18) , but since the reader may mistakenly infer from the name sno-dE3 that it is missing exon 3 entirely and is a mutant or minor variant, we prefer SnoN2. SnoN2 is often the major expressed mRNA from the mouse Sno gene and is also expressed in human tissues. The 138 nt alternative segment starts with a consensus splice donor GT dinucleotide and ends at the exon 3/4 junction, so the use of an alternative 5′ splice donor is a likely mechanism for generation of the two forms. It cannot be generated by mutually exclusive splicing of alternative exons, as occurs upstream in the human Sno gene, since the alternatively spliced 138 nt segment is on the same exon as the upstream 96 nt (18) .
We cloned and sequenced SNON2 mRNAs from human tissue and confirmed that human SNON2 is spliced as in the mouse, remaining in-frame and predicting translation of a similar SNON2 protein missing 46 amino acid residues (Fig. 1) . SNON2 constitutes only 1-2% of the SNO mRNA (Fig. 2C) . SnoN2 is the most abundant Sno isoform in many mouse tissues ( Fig. 3; 18) . Three out of 43 clones obtained during RT-PCR cloning were SNON2, agreeing with our RT-PCR data that SNON2 is not extremely rare. These were full-length clones and thus did not have a significant size advantage in the PCR reaction or cloning.
A schematic summary of the Ski/Sno family is presented in Figure 6 . We note that there is alternative splicing in Ski but not Sno in birds and in Sno but not Ski in mammals. The mouse SNON and SNON2 isoforms contain 10 fewer amino acid residues than the human because of small internal deletions (Fig. 1) . Human SNOA, SNOI and SNON have been previously described (14, 15) , but the exon structure and additional SNON2 isoform are just emerging (this paper; 18,33).
Definition of the exon structure in mouse Sno (18) and its confirmation in human (this paper, Figs 1 and 6) suggests that the human SNOA structure previously described (14) results from usage of an alternative version of exon 2. The SNOI sequence divergence was previously thought to result from an alternative version of exon 3 in which the divergent insertion region is flanked by identical regions (15) . That was called exon 3 in anticipation of finding mammalian homologs for the 'exon 2' that is alternatively spliced in chicken c-Ski, but which we now know is absent from mammalian Ski and Sno. However, since there is a small exon 2 in mammalian Sno that is not a separate exon in the chicken Sno gene, it is after all exon 3 ( Fig. 1; 18,33) . Now that the exon structure in mouse and human Sno is defined, it is clear that the SNOI divergence begins at the start of what we now call exon 3 (Figs 1 and 6 ) and may arise from splicing of an alternative version of exon 3. SNOI could not be produced by failure to excise an intron, since there is not a consensus 5′ splice site in the SnoI cDNA sequence at the point of divergence nor a 3′ consensus site at the point where SNOI unique sequence rejoins SNON, as noted previously (15) . We have not experimentally confirmed that the SNOI sequence is an alternative exon flanked by consensus splice sites in the genome; sequencing of the human SNO gene will resolve this. SnoN2 described here and previously (18) arises from alternative use of a splice donor within exon 3; this occurs rarely in humans, but SnoN2 is often the most abundant Sno species expressed in the mouse. Future experiments will define whether these isoforms function differently.
SnoN/N2 expression is diminished in adult mouse skeletal muscle compared with neonatal skeletal muscle (Fig. 3) . Ski expression is elevated in the regenerating axolotl limb blastema (40) . It will be of interest to examine whether SnoN/N2 expression is increased in regenerating muscle when satellite cell proliferation is stimulated.
Sno expression is induced upon serum stimulation of quiescent fibroblasts, even when stimulated in the presence of the protein synthesis inhibitor cycloheximide. In contrast, Ski is not induced by serum stimulation in this cell type. Thus, Sno is an immediate early gene but Ski is not. Immediate early genes are those that are induced without requiring protein synthesis; delayed early genes are those that require protein synthesis for induction. Some authors refer to immediate early genes as those induced minutes after stimulation and delayed early as those induced hours after stimulation, both in the absence of protein synthesis (41) . Sno induction is detectable by 30 min, so it is also immediate early by this criterion. Another term is proliferation stimulus-responsive gene (41) . Such early response genes are thought to play important roles in regulation of the re-entry of cells into the cell cycle. We found that the SnoN2 isoform is much more strongly induced than SnoN. This raises the possibility that there may be regulatory influences on the alternative splicing that produces the SnoN2 isoform.
Many immediate early genes are cell cycle regulated but some are not; this may depend on the cell type assayed (41) . We showed earlier that Ski and Sno expression is modulated in a different cell type, peaking in early to mid G 1 in synchronized myeloid cells in response to progress in the cell cycle (12) . Thus, Sno is both proliferation stimulus responsive in fibroblasts and cell cycle regulated in myeloid cells. In contrast, Ski is not proliferation stimulus responsive in fibroblasts but is cell cycle regulated in myeloid cells. In addition Ski responds to IL-3 or GM-CSF growth factor depletion and addition in myeloid cells (12) , whereas Sno does not (Pearson-White, unpublished results). Ski is induced 6-fold by phorbol ester administration in megakaryocytic hematopoietic cells (11) . Thus, there are differences in growth factor responses and cell type-specific cell cycle regulation between the Ski and Sno genes. These data are consistent with potential differing roles for Ski and Sno in regulating the response of different cell types to extracellular signals in which they either enter (proliferate) or exit from (terminally differentiate) the cell cycle.
